As a result of falling demand and the introduction of competing vaccines, AstraZeneca has decided to discontinue production of the Vaxzevria coronavirus vaccine. With almost 3 billion doses administered worldwide since its launch in January 2021, the vaccine—developed in conjunction with the University of Oxford—has been a prominent participant in the global vaccination effort.
Having said that, the corporation has admitted that the vaccine has not brought in any money since April 2023. Reduced demand has led AstraZeneca to begin the process of withdrawing marketing authorizations for Vaxzevria in Europe.
There will be no more marketing or sale of Vaxzevria in nations of the European Union as the withdrawal has been certified by the European Medicines Agency. AstraZeneca intends to collaborate with foreign regulators to revoke marketing authorizations in areas where the company does not anticipate future commercial demand.
Regardless of the withdrawal, AstraZeneca was proud of Vaxzevria’s contribution to the worldwide response to the epidemic. On the other hand, Dr. Michael Head of the University of Southampton pointed out that alternative vaccines, especially mRNA vaccines made by companies like Pfizer and Moderna, are better since they are more effective and can adapt to new strains.
Problems have arisen along the way for AstraZeneca and Vaxzevria, including criticism for blunders made during clinical trials, delays in production, and worries about uncommon side effects including blood clotting. Regardless of these obstacles, the vaccine nonetheless managed to sell well in 2021, even though AstraZeneca is currently dealing with a class action litigation in the UK over purported vaccination injuries.
Comment Template